Detection reagent for detecting at least one anti-phospholipid antibody, kit and application thereof

By combining cardiolipin immunomagnetic microspheres and β2-GP1 treatment agent, the accuracy of detection of anti-phospholipid antibodies in the prior art was solved, and more stable and accurate detection results were achieved.

CN118914540AActive Publication Date: 2024-11-08SHENZHEN NEW INDS BIOMEDICAL ENG CO LTD

Patent Information

Application Number
CN202310502401.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08
Estimated Expiration
2043-05-06

AI Technical Summary

Technical Problem

The methods for detecting antiphospholipid antibodies in the prior art are susceptible to external influences, resulting in dissociation of the solid phase and cardiolipin, and modifying the natural cardiolipin will change its properties and lead to inaccurate detection results.

Method used

Immunomagnetic microspheres of cardiolipin, containing magnetic nanoparticles and spherical liposomes with a bilayer membrane structure. The magnetic nanoparticles are coated with cardiolipin to form superparamagnetic cardiolipin immunomagnetic microspheres for detection of anti-phospholipids. Antibodies are added and β2-GP1 treatment agent is added during the detection process to simulate the in vivo reaction of the machine.

Benefits of technology

Improve the accuracy of anti-phospholipid antibody detection, maintain the antigenic properties of natural cardiolipin, enhance the stability and accuracy of the detection, and can accurately detect anti-cardiolipin antibodies, anti-β2-GP1 antibodies, anti-cardiolipin and β2-GP1 Complex antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention provides a detection reagent for detecting at least one anti-phospholipid antibody, a kit and application. The cardiolipin immunomagnetic microsphere containing a magnetic nanoparticle body and a spherical liposome containing cardiolipin is adopted, the magnetic nanoparticle has superparamagnetism, and the cardiolipin has the amphoteric characteristics of a hydrophilic head and a hydrophobic tail, so that the characteristic that the liposome can be formed is utilized; a liposome layer containing cardiolipin is formed on the surface of the magnetic nanoparticle, and then the cardiolipin immunomagnetic microsphere with superparamagnetism is prepared. In the process, the central phospholipid does not need to be chemically modified, the prepared detection reagent of the cardiolipin immunomagnetic microspheres maintains the antigen property of the cardiolipin to a great extent, and the accuracy of detection of anti-phospholipid antibody items is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of in vitro detection, and in particular to a detection reagent, a detection kit and applications thereof for detecting at least one antiphospholipid antibody. Background Art

[0002] Antiphospholipid syndrome (APS) is an autoimmune non-inflammatory disease that is associated with vascular endothelial cells, monocytes, and macrophages, leading to functional abnormalities in thrombosis and fibrinogen degradation. The clinical manifestations are mainly venous and arterial thrombosis, among which venous thrombosis is most common in deep vein thrombosis of the lower extremities, while arterial thrombosis is most common in thrombosis. Habitual abortion is the most common pregnancy complication in APS patients. At present, the primary cause is still unclear, and it may be related to genetic, infection and other factors. The prevalence in the population is about 20-50 / 100,000, among which the male-to-female ratio is about 1:9, and the incidence rate is about 5 / 100,000. The recurrence of antiphospholipid syndrome is associated with an increased risk of late miscarriage. About 20% of patients with recurrent miscarriage are caused by antiphospholipid syndrome.

[0003] Currently, the common detection indicators of antiphospholipid antibody syndrome are lupus anticoagulant, antiphospholipid antibodies and anti-β2-GP1 antibodies.

[0004] The main method for detecting antiphospholipid antibodies in the prior art is to fix cardiolipin on a solid phase by physical adsorption or chemical connection. Among them, physical adsorption is easily affected by external factors, resulting in the dissociation of the solid phase and cardiolipin. In the method of chemical connection, it is usually necessary to modify natural cardiolipin. Cardiolipin is a small molecule composed of two phosphate molecules and three glycerol molecules forming a skeleton structure, which is then connected to four fatty acid molecules. Modification of natural cardiolipin often leads to changes in the properties of cardiolipin, resulting in inaccurate test results. Summary of the invention

[0005] Based on the problems existing in the prior art, the first aspect of the present invention provides a detection reagent for detecting at least one antiphospholipid antibody, which comprises cardiolipin immunomagnetic microspheres, wherein the cardiolipin immunomagnetic microspheres comprise magnetic nanoparticles and spherical liposomes containing cardiolipin, and the spherical liposomes are coated on the surface of the magnetic nanoparticles.

[0006] Furthermore, the liposome is a liposome with a double-layer membrane structure.

[0007] Furthermore, the mass proportion of cardiolipin in liposomes is 50%-100%.

[0008] Furthermore, the double-layer membrane structured liposomes further include one or more selected from phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, cholesterol, and dipalmitoylphosphatidylcholine.

[0009] Furthermore, the particle size of the magnetic microspheres ranges from 50 to 100 nM.

[0010] Furthermore, the surface of the liposome is negatively charged.

[0011] The second aspect of the present invention provides a detection kit for detecting at least one antiphospholipid antibody, wherein any one of the detection reagents described above is included.

[0012] Furthermore, the detection kit also includes a treatment agent containing β2-GP1.

[0013] The third aspect of the present invention provides a method for detecting antiphospholipid antibodies, characterized in that it comprises the steps of 1) reacting the sample to be tested with any of the aforementioned detection reagents to form an immune complex, 2) detecting antiphospholipid antibodies in the sample through the immune complex.

[0014] Furthermore, before forming the immune complex, the method further includes reacting the sample with a treatment agent containing β2-GP1.

[0015] Alternatively, before forming the immune complex, the method further comprises a step of reacting any of the aforementioned detection reagents with a treatment agent containing β2-GP1.

[0016] Furthermore, while or after the formation of the immune complex, it reacts with another detection reagent containing a detection marker, and then the anti-cardiolipin antibodies, anti-β2-GP1 antibodies and antibodies against the complex of cardiolipin and β2-GP1 in the sample are determined by the detection marker.

[0017] The present application adopts cardiolipin immunomagnetic microspheres containing magnetic nanoparticles and spherical liposomes containing cardiolipin, and utilizes the superparamagnetism of magnetic nanoparticles and the amphiphilic characteristics of cardiolipin with a hydrophilic head and a hydrophobic tail to form liposomes. A liposome layer containing cardiolipin is formed on the surface of the magnetic nanoparticles, thereby preparing cardiolipin immunomagnetic microspheres with superparamagnetism. In this process, cardiolipin does not need to be chemically modified and maintains its natural state. The detection reagent containing the cardiolipin immunomagnetic microspheres maintains the antigenic properties of cardiolipin to a great extent, and improves the accuracy of antiphospholipid antibody detection. Implementation

[0018] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.

[0019] The first aspect of the present invention provides an anti-cardiolipin antibody detection reagent, which comprises cardiolipin immunomagnetic microspheres, wherein the cardiolipin immunomagnetic microspheres comprise a magnetic nanoparticle body and a liposome containing cardiolipin, and the liposome is coated on the surface of the magnetic nanoparticle body.

[0020] Since magnetic nanoparticles have superparamagnetism, cardiolipin has the amphiphilic characteristics of a hydrophilic head and a hydrophobic tail, and can form liposomes. A liposome layer containing cardiolipin is formed on the surface of the magnetic nanoparticles. In this process, cardiolipin does not need to be chemically modified, and maintains its natural state, which greatly maintains the antigenic properties of cardiolipin and improves the accuracy of detection.

[0021] It should be noted that the liposomes are coated on the surface of the magnetic nanoparticle body, which means that the liposomes form independent chambers in a liquid environment, and the magnetic nanoparticle body is located inside the chambers.

[0022] In some embodiments of the present application, the surface of the cardiolipin immunomagnetic microspheres is negatively charged. Since the cardiolipin immunomagnetic microspheres are charged, the formed liposomes are not easy to agglomerate and have stability.

[0023] In some embodiments of the present application, the liposome is a liposome with a double-layer membrane structure, in which the mass proportion of the central phospholipids is 50%-100%.

[0024] In some embodiments of the present application, the liposome with a double-layer membrane structure further includes one or more selected from phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, cholesterol, and dipalmitoylphosphatidylcholine.

[0025] In some embodiments of the present application, the particle size of the magnetic microspheres ranges from 50-100 nM.

[0026] In some embodiments of the present application, cardiolipin immunomagnetic microspheres can be obtained by a variety of preparation methods, such as reverse evaporation method, thin film method, ultrasonic method and double emulsion method. An exemplary preparation method is as follows: a chloroform solution containing cardiolipin (CL), cholesterol (Ch) and dipalmitoylphosphatidylcholine (DPPC) is dried by vacuum rotary evaporation in a round-bottom flask. The obtained lipid film is redissolved in chloroform and the solvent is evaporated. This drying and dissolution is repeated 3 times. The obtained lipid film is kept under high vacuum for at least 3 h, and then phosphate buffer and ferroferric oxide magnetic nanoparticles are added at room temperature for hydration. After ultrasonication with a probe, centrifugation is performed, and the middle brown aqueous suspension is taken to obtain liposomes containing cardiolipin.

[0027] The obtained reaction solution is centrifuged to remove the supernatant, and a magnetic bead washing solution is added for washing, and this washing step is repeated four times; after washing, a magnetic bead suspension solution is added for suspension to obtain a cardiolipin immunomagnetic microsphere suspension solution.

[0028] The second aspect of the present application provides a detection kit for detecting at least one antiphospholipid antibody, wherein any one of the detection reagents described above is included.

[0029] Furthermore, the detection kit also includes a treatment agent containing β2-GP1.

[0030] The third aspect of the present application also provides a method for detecting at least one antiphospholipid antibody, which comprises the steps of: The sample to be tested is reacted with any of the aforementioned detection reagents containing cardiolipin immunomagnetic microspheres to form an immune complex, and at least one of the antiphospholipid antibodies in the sample is detected through the immune complex.

[0031] In some embodiments of the present application, the antiphospholipid antibodies in the sample are anti-cardiolipin antibodies.

[0032] In some embodiments of the present application, the antiphospholipid antibody detection method further comprises a step of reacting the sample or any of the aforementioned detection reagents with a treatment agent containing β2-GP1 before forming the immune complex.

[0033] β2-GP1 is a plasma cofactor for aPL (anti-phospholipid antibody APL) to bind to cardiolipin. It is a glycoprotein synthesized by the liver and exists in the plasma at a concentration of about 200 mg / L. Its relative molecular mass is about 50kDa. Studies have shown that β2-GP1 exists in two different conformations in plasma: cyclic (closed) and open, of which the open is its active state. In purified plasma, the proportions of cyclic and open are 91% and 9%, respectively, that is, β2-GP1 mainly circulates in the blood in a closed-loop conformation. This closed-loop structure shields the antigenic epitope of the anti-β2-GP1 antibody in plasma. After β2-GP1 circulating in the blood in a closed-loop conformation binds to the mitochondrial membrane containing cardiolipin, its conformation changes and it is converted into an activated open-type β2-GP1. The antigenic epitope of the first domain is exposed, stimulating the body to produce anti-β2-GP1 antibodies and antibodies to the complex of cardiolipin and β2-GP1, thereby causing autoimmune diseases.

[0034] Since the cardiolipin on the cardiolipin immunomagnetic microspheres is similar to the structure of the cardiolipin on the biological membrane in the body, the conformational change induced in β2-GP1 is also closer to the reaction in the body. By adding β2-GP1 to the detection reagent before adding the sample to be tested, β2-GP1 is fully reacted with the cardiolipin immunomagnetic microspheres, and then the sample to be tested is added for reaction. Due to the simulation of the reaction in the body, the anti-cardiolipin antibodies, anti-β2-GP1 antibodies and antibodies against the complex of cardiolipin and β2-GP1 in the sample to be tested can be more accurately detected.

[0035] In some embodiments of the present application, the detection method comprises first reacting the sample with a treatment agent containing β2-GP1.

[0036] In some embodiments of the present application, the method for detecting antiphospholipid antibodies includes reacting a sample treated with an appropriate amount of β2-GP1 with the aforementioned detection reagent containing cardiolipin immunomagnetic microspheres to form a second immune complex. By detecting the immune complex, it can be used to detect antiphospholipid antibodies, β2-GP1 antibodies, and antibodies against cardiolipin and β2-GP1 complexes in the sample.

[0037] In some embodiments of the present application, the method for detecting antiphospholipid antibodies comprises: By adding β2-GP1 to the detection reagent before adding the sample to be tested, β2-GP1 and cardiolipin immunomagnetic microspheres are fully reacted, and the prepared microspheres are then added to the sample to be tested for reaction to form immune complexes. The immune complexes can be used to detect anti-cardiolipin antibodies, β2-GP1 antibodies, and antibodies against the complex of cardiolipin and β2-GP1 in the sample.

[0038] The present application can detect multiple antibodies using one detection reagent by reacting a treatment agent containing β2-GP1 with a detection reagent or a test sample containing cardiolipin immunomagnetic microspheres.

[0039] In some embodiments of the present application, the antiphospholipid antibody detection method further comprises the step of reacting with another detection reagent containing a detection marker while or after forming the immune complex, and then determining the antiphospholipid antibodies in the sample through the detection marker.

[0040] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in this application can be purchased from the market or prepared by existing methods.

[0041] The beneficial effects of the present application will be further explained in detail below in conjunction with specific embodiments.

[0042] Example 1: Preparation of cardiolipin immunomagnetic microspheres.

[0043] 1) Preparation of magnetic nanoparticles: 0.2 g of ferric chloride, 0.1 g of ferric dichloride and 0.05 g of polyethylene glycol octyl phenyl ether were added to 10 ml of water to prepare a solution with a concentration of 20 mg / ml ferric chloride, 10 mg / ml ferric dichloride and 5 mg / ml polyethylene glycol octyl phenyl ether. The solution was stirred vigorously for 30 minutes at 50°C in an inert atmosphere, and the pH value was adjusted to 8 with a 3M sodium hydroxide solution. The temperature was maintained, and stirring was continued for 30 minutes, and then centrifuged and washed with deionized water and ethanol, respectively, to obtain ferroferric oxide nanoparticles.

[0044] In 20mL ultrapure water, 129.76mg of ferric chloride (anhydrous FeCl3) and 79.53mg of ferrous chloride tetrahydrate (FeCl2.4H2O) were added to prepare ferric chloride and ferrous chloride solutions with a concentration of 0.04M / L, and the molar ratio of Fe2+ / Fe3+ was kept at 1 / 2. At 25°C and inert gas N2 atmosphere, the mixture was stirred at 2500rpm for 10min, and then 27% concentrated NH4OH was added to control the pH of the reaction system at 10.5. After stirring for 30 minutes, the mixture was centrifuged, washed with ultrapure water and anhydrous ethanol for 3 times, and finally dried at 40°C to obtain ferrosoferric oxide magnetic nanoparticles.

[0045] 2) Preparation of cardiolipin magnetic nanoparticles: A chloroform solution containing cardiolipin, phosphatidylserine, cholesterol, and dipalmitoylphosphatidylcholine was dried by vacuum rotary evaporation in a round-bottom flask (specific addition concentrations are shown in Table 1). The obtained lipid film was dissolved in chloroform and the solvent was evaporated. Drying and dissolving were repeated 3 times. The obtained lipid film was kept under high vacuum for at least 3 h, and then 100 ml of pH = 7.4 phosphate buffer and 10 mg of the prepared ferroferric oxide nanoparticles were added at room temperature for hydration. After ultrasonication with a probe for 60 minutes, centrifugation was performed, and the supernatant and the unencapsulated magnetic material at the bottom of the bottle were discarded. The brown aqueous suspension in the middle layer was taken to obtain the cardiolipin immunomagnetic microsphere solution.

[0046] Table 1 Phospholipid types and concentrations added.

[0047]

[0048] 3) The reaction solution obtained in step 2) was centrifuged to remove the supernatant, and magnetic bead washing solution was added for washing, and this washing step was repeated four times; wherein the magnetic bead washing solution was 0.1M pH 7.4 PBS buffer, after adding and mixing, 0.5% (w / v) BSA was weighed and autodissolved and mixed.

[0049] 4) After washing, add a magnetic bead suspension to suspend the microspheres to obtain a cardiolipin immunomagnetic microsphere suspension; wherein the magnetic bead suspension is a 0.1 M pH 7.4 PBS buffer.

[0050] Example 2: Cardiolipin antibody IgG detection kit, comprising:

[0051] (1) Component A: one of the cardiolipin immunomagnetic microsphere solutions obtained in Example 1, wherein the working concentration of the cardiolipin immunomagnetic microspheres is 1 mg / ml.

[0052] (2) Component B: mouse anti-human IgG secondary antibody solution labeled with a luminescent marker, wherein the working concentration of the luminescent marker is 15 ng / ml, and the working concentration of the mouse anti-human IgG secondary antibody is 200 ng / ml. The luminescent marker is selected from any one of the following: luminol and its derivatives, isoluminol and its derivatives, horseradish peroxidase, and alkaline phosphatase.

[0053] (3) Calibrator solution: a low-concentration calibrator solution containing 15.826AU / mL cardiolipin antibody IgG and a high-concentration calibrator solution containing 281.215AU / mL cardiolipin antibody IgG. Each component contains BSA and a preservative, the mass volume percentage concentration of BSA is 0.1%, and the preservative is sodium azide.

[0054] Example 3: A chemiluminescent immunoassay method for detecting anti-cardiolipin antibody IgG.

[0055] The detection kit shown in Example 2 is used for detection, comprising the following steps: 1) Add the sample solution to be tested, the high point calibrator and the low point calibrator into different reaction cup wells respectively; 2) adding component A to step 1) respectively to allow it to bind with the substance to be tested; 3) adding component B to step 2) respectively, so that the mouse anti-human IgG secondary antibody labeled with the luminescent marker binds to the cardiolipin immunomagnetic microspheres and the substance to be tested; wherein the incubation temperature is 37° C. and the incubation time is 10 min; 4) Magnetic separation to obtain a conjugate of mouse anti-human IgG secondary antibody labeled with a luminescent marker, magnetic microspheres coated with cardiolipin, and the substance to be tested; 5) adding a luminescent excitation substrate to the conjugate obtained in step 4) and detecting the intensity of the light signal; wherein the luminescent excitation substrate is NaOH and H2O2; 6) The antiphospholipid antibody concentration of the sample to be tested is automatically calculated based on the working curve corrected by the calibrator and the light intensity of the sample detection.

[0056] Detection limit evaluation results

[0057] According to the ingredients and concentrations of each component provided in Example 2, kits containing Examples 11-14 were prepared, and one kit was extracted from each kit. Four serum samples with a concentration of 0.6-0.9 AU / mL were prepared by adding an anti-cardiolipin enterprise calibrator (the component was cardiolipin antibody IgG with a concentration of 554684 AU / mL, 10 mM pH 7.4 PBS buffer, and a preservative of sodium azide) to blank serum. The samples were numbered LDs1, LDs2, LDs3, and LDs4 for testing. The test was continued for 3 days, and each sample was tested 5 times per day. The results of 15 repeated tests for each sample were recorded, and the LoD value of the reagent was calculated by the relevant formula. The calculation formula is as follows: 1) Count the number of all sample test results below LoB, and calculate the proportion of test results below LoB (P=n / 60x100%); 2) If P is less than or equal to 5%, the median value of all test results of the batch of reagents is used as the LoD; if P exceeds 5%, a sample with a higher concentration is selected to re-evaluate the LoD; Calculated and verified according to the above steps, the detection limits of the kit containing Examples 11-14 were 0.791, 0.813, 0.768, and 0.834 AU / mL.

[0058] Repeatability evaluation results

[0059] According to the ingredients and concentrations of each component provided in Example 2, kits containing Examples 11-14 were prepared, and one box of the kit was extracted from each kit. The quality control product 1 and quality control product 2 provided in the kit were measured respectively. The quality control product 1 and quality control product 2 were measured 10 times each, and the mean value (M) and standard deviation (SD) of the 10 measurement results of each quality control product were calculated. The coefficient of variation (CV) was calculated according to formula (1). The calculation formula is as follows: CV=SD / M×100% ……………………………………………(1) Where: CV – coefficient of variation; SD——standard deviation of the measurement results; M is the average value of the measurement results.

[0060] According to the above steps, it was calculated and verified that the CV values ​​of the repeatability evaluation of the kit containing Examples 11-14 at two levels of different concentrations were all within the range of 8%.

[0061] The experimental results show that the detection reagent containing cardiolipin immunomagnetic microspheres used in the present application has good repeatability in detecting anti-cardiolipin antibodies.

[0062] Accuracy Assessment

[0063] The antiphospholipid enterprise calibrator (components of 554684AU / mL phospholipid antibody IgG, 10mM pH7.4 PBS buffer, and preservative sodium azide) was prepared into 50.000AU / mL calibrators (A1) and 300.000AU / mL calibrators (A2) using a zero concentration calibrator. A routine test sample (B) (low-value serum) was selected and divided into three equal volumes. The calibrator (A1) and the calibrator (A2) were added to two of the samples, respectively, and the volume ratio of the added A1, A2 and B was 1:9 to prepare the samples to be recovered and analyzed. The same volume of samples without the analyte to be tested and the same matrix were added to the third routine test sample to prepare the basic sample. According to the ingredients and concentrations of each component provided in Example 2, a kit containing Examples 11-14 was prepared, and one box of the kit was extracted from each kit. The samples to be recovered and analyzed and another basic sample were repeatedly measured 3 times, and the average was calculated. The recovery rate was calculated according to formula (2): ………………………………………………………………(2) Where: R ——Recovery rate, %; C ——The mean value of the concentration of samples to be recovered and analyzed; C 0——Mean value of basic sample concentration determination; C S ——The theoretical concentration of the added analyte.

[0064] According to the above steps, the recovery rates of the kit containing Examples 11-14 for the New Industry Bio anti-cardiolipin antibody IgG reagent calibrator A1 and calibrator A2 were calculated and verified to be within the range of [90.0%, 110.0%].

[0065] The experimental results show that the detection reagent containing cardiolipin immunomagnetic microspheres used in the present application has good accuracy in detecting anti-cardiolipin antibodies.

[0066] Linear Interval Evaluation The antiphospholipid company calibrator (components of phospholipid antibody IgG with a concentration of 554684AU / mL, 10mM pH7.4 PBS buffer, and sodium azide as preservative) was prepared into samples with theoretical concentrations of 450.000 AU / mL (high value sample H) and 1.000 AU / mL (low value sample L) using a zero concentration calibrator, and then the H point concentration sample and the L point concentration sample were used for equal concentration interval dilution to obtain 6 samples with different concentration levels (as shown in Table 1). According to the ingredients and concentrations of each component provided in Example 2, a kit containing Examples 11-14 was prepared, and one box of the kit was extracted from each kit, and the samples at each concentration level were measured three times, and the mean of the measurement results was calculated. The mean value of the measured concentration was linearly fitted with the theoretical concentration using the least squares method, and the linear correlation coefficient ( r ).

[0067] Table 2 Preparation of samples at 6 different concentration levels obtained by equal concentration interval dilution.

[0068]

[0069] According to the above steps, the linear correlation coefficients of the kits containing Examples 11-14 were calculated and verified to be greater than 0.9900, meeting the requirements.

[0070] Embodiment 4: A detection kit for detecting at least one antiphospholipid antibody, comprising.

[0071] (1) Component A: the detection reagent obtained in Example 11, wherein the working concentration of cardiolipin immunomagnetic microspheres is 1 mg / ml.

[0072] (2) Component B: mouse anti-human IgG secondary antibody solution labeled with a luminescent marker, wherein the working concentration of the luminescent marker is 15 ng / ml, and the working concentration of the mouse anti-human IgG secondary antibody is 200 ng / ml. The luminescent marker is selected from any one of the following: luminol and its derivatives, isoluminol and its derivatives, horseradish peroxidase, and alkaline phosphatase.

[0073] (3) Component C: a treatment agent containing β2-GP1, wherein the working concentration of β2-GP1 is 3 ug / mL and the buffer is 10 mM pH 7.4 PBS.

[0074] (4) Calibrator solution: a low-concentration calibrator solution with a β2-GP1 antibody concentration of 15.826AU / mL and a high-concentration calibrator solution with a β2-GP1 antibody concentration of 281.215AU / mL. Each component contains BSA and a preservative, the mass volume percentage concentration of BSA is 0.1%, and the preservative is sodium azide.

[0075] The antiphospholipid antibody IgG detection kit of this embodiment is used to detect known samples to be tested.

[0076] The known information of the samples to be tested is as follows.

[0077] The detection steps include: 1) Add different sample solutions to different reaction cups, add component A to bind to the substance to be tested, add component B to bind the mouse anti-human IgG secondary antibody labeled with the luminescent marker to the immune complex on the cardiolipin immunomagnetic microspheres; the incubation temperature is 37°C and the incubation time is 10 minutes. Obtain test result 1.

[0078] 2) Add different sample solutions to different reaction cups, then add component A and component C, react fully, wash; add component B to allow the mouse anti-human IgG secondary antibody labeled with the luminescent marker to bind to the immune complex on the cardiolipin immunomagnetic microspheres; the incubation temperature is 37°C and the incubation time is 10 minutes. Obtain test results 2 Test result 1 is used to determine whether the sample contains antiphospholipid antibodies, and test result 2 is used to determine whether the sample contains antiphospholipid antibodies, anti-β2-GP1 antibodies, and phospholipid and β2-GP1 complex antibodies.

[0079] The actual measurements are as follows:

[0080] This indicates that the addition of β2-GP1 to a kit containing a detection reagent of cardiolipin immunomagnetic microspheres containing cardiolipin liposomes can be used to detect multiple antiphospholipid antibodies in a sample.

[0081] Positive sera from 56 patients with antiphospholipid syndrome and sera from 201 normal subjects were collected, and the specificity and sensitivity were evaluated using the kits of Example 2 (containing the cardiolipin detection reagent of Example 11) and Example 4, respectively. The results are as follows.

[0082] Table 3 Specificity and sensitivity evaluation of different embodiments

[0083] This shows that the detection kit of the present application has good specificity for detecting patients with antiphospholipid syndrome. The kit of Example 4 containing β2-GP1 treatment agent has higher sensitivity.

[0084] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A detection reagent for detecting at least one antiphospholipid antibody, characterized in that: The cardiolipin immunomagnetic microspheres include magnetic nanoparticle bodies and spherical liposomes containing cardiolipin, and the spherical liposomes are coated on the surface of the magnetic nanoparticles.

2. The detection reagent according to claim 1, characterized in that The liposome is a liposome with a double-layer membrane structure. Preferably, the double-layer membrane liposome further comprises one or more selected from phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, cholesterol, and dipalmitoylphosphatidylcholine.

3. The detection reagent according to claim 1, characterized in that The mass proportion of cardiolipin in liposomes is 50%-100%.

4. The detection reagent according to claim 1, characterized in that The liposome surface is negatively charged.

5. A test kit for detecting at least one antiphospholipid antibody, characterized in that The method comprises any one of the detection reagents described in claims 1 to 4.

6. The detection kit according to claim 5, characterized in that The kit also includes a treatment agent containing β2-GP1.

7. A method for detecting at least one antiphospholipid antibody, characterized in that: The following steps are included: The sample to be tested is reacted with any one of the detection reagents described in claims 1 to 4 to form an immune complex, At least one of the antiphospholipid antibodies in the sample is detected by the immune complex.

8. The detection method according to claim 7, characterized in that: Before forming the immune complex, the method further comprises the step of reacting the sample to be tested with a treatment agent containing β2-GP1.

9. The detection method according to claim 7, characterized in that: Before forming the immune complex, the method further comprises a step of reacting the detection reagent with a treatment agent containing β2-GP1.

10. The detection method according to claim 7, characterized in that: The immune complex is formed and reacted with another detection reagent containing a detection label at the same time or after the immune complex is formed, and at least one of the anti-cardiolipin antibody, anti-β2-GP1 antibody and anti-cardiolipin and β2-GP1 complex antibody in the sample is detected through the detection label.

Citation Information

Patent Citations

  • Modified cardiolipin coated magnetic nanobead and preparation method thereof

    CN106198957A

  • Anti-cardiolipin antibody IgG magnetic particle chemiluminiscence immunoassay kit

    CN111323577A

  • Magnetic particle chemiluminescence reagent and kit for quantitative detection of anticardiolipin antibody

    CN116068172A

  • Phosphatidylserine coating magnetic particle, and screening method of phosphatidylserine bonding molecule using it

    JP2009244157A

  • Temperature-responsive magnetic fine grains having surface modified by oleophilic molecule, and composition forming ribosome-like structure containing the fine grains and amphipathic molecule

    JP2010066200A

Cited By

  • Matrix for humanized antibody calibrator and calibrator thereof

    CN119804067A